Zimbabwe boosting Clinical research with US Training

The country’s clinical research programme has received a massive boost following the unveiling of an exchange programme that shall see University of Zimbabwe postgraduate students receiving further research training in HIV and AIDS clinical trials at the University of Buffalo in the United States.

The country’s clinical research programme has received a massive boost following the unveiling of an exchange programme that shall see University of Zimbabwe postgraduate students receiving further research training in HIV and AIDS clinical trials at the University of Buffalo in the United States.

The move is expected to improve Zimbabwe’s ability to deal with HIV and AIDS.

Speaking on the sidelines of the exchange programme launch held in the capital, University of Zimbabwe Vice Chancellor Professor Levy Nyagura said the programme shall see 15 postgraduates from the UZ benefiting over the next five years.

“The students will in turn offer clinical pharmacology expertise to multidisciplinary teams to achieve the HIV and AIDS research goals for Zimbabwe…” said Nyagura.

Buffalo University Associate Dean Professor Gene Morse said his institution chose to partner the University of Zimbabwe following what he termed reputable expertise associated with the college’s medical clinic.

“University of Zimbabwe has a history of credibility. It has also become a universal phenomenon that the world concentrates on research to do with dealing with the pandemic…”revealed Prof Morse.

Recent studies have also discovered that Microbicides are drugs that are intended for use to prevent infection with sexually transmitted infections, such as HIV.

Current investigations have shown that Microbicides might give hope to many women as they may be able to use them to protect themselves from being infected by HIV and other infections.

Advertisements

Korean Contract Research Organization to Use Oracle Clinical and Oracle Remote Data Capture

Jul 22, 2009 08:00 ET

DreamCIS Selects Oracle® Health Sciences Applications to Accelerate and Simplify Clinical Trial Data Collection

Leading Korean Contract Research Organization to Use Oracle Clinical and Oracle Remote Data Capture Applications

News Facts

  • DreamCIS, a leading contract research organization (CRO) in Korea, has selected Oracle® Health Sciences applications to help increase efficiency in clinical trials data collection and improve data quality.
  • DreamCIS required a robust, reliable and scalable clinical trial management system to replace its legacy clinical software solution and help enable the company’s biometrics center to become an Asian clinical trial data management hub.
  • DreamCIS intends to use Oracle Clinical and Oracle Remote Data Capture (RDC) 4.5.3 to help meet global standards for clinical trials data management and achieve higher quality local clinical trial services.
  • Oracle Health Sciences provides the life sciences sector with the most integrated clinical data management and electronic data capture applications available today, while also providing best-in-class functionality.
  • Oracle RDC 4.5.3 uses the same data model as Oracle Clinical, ensuring tight integration of data between these applications.
  • Oracle RDC 4.5.3 is also completely Web-based, with a ‘zero client footprint’ for the HTML data entry window. This enables improved global access and performance for life sciences organizations to conduct global clinical studies more cost effectively whether using traditional pen and paper, electronic data capture, or hybrid methods.
  • Oracle Clinical and Oracle Remote Data Capture are widely adopted by global health science organizations including CROs, pharmaceutical and biotechnology companies. DreamCIS is the first CRO in Korea to adopt the applications.

Supporting Quotes

  • “Oracle Health Sciences applications are not only equipped with outstanding technology but also offer superior system reliability, compatibility and compliance,” said Hee-Joong Koh, Director, Biometrics Center, DreamCIS. “Oracle’s proven experience in the health sciences sector was important to us and we believe their solutions will enable us to raise our data management levels to global standards, and help us become the leader in the Asian clinical trial markets in the future.”
  • “As the number of clinical trials increases in the Korean market and throughout Asia, there is a growing need for best-in-class software applications for clinical development and drug safety,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. “We are committed to helping emerging CROs like DreamCIS accelerate insights for better health and look forward to supporting their efforts to become an important hub for clinical data management in the region.”

Supporting Resources

%d bloggers like this: